Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.
Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, Zhang G, Lu A, Yang Z. · 2018
Read Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review. by Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, Zhang G, Lu A, Yang Z. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5796144.txt.
Introduction
Riaz and co-authors review ways to aim liposomes at solid tumors. Liposomes are tiny fat bubbles that carry cancer drugs. Loaded drugs cause fewer side effects than free ones. Yet body barriers and tumor conditions block delivery. Surface engineering tries to beat those blocks.
The review sorts targets on cancer cells, inside them, and in the tumor's vessels and surroundings. Ligands and surface methods for each target are described. Some liposomes release their cargo when they sense heat, acid, or other cues. Fresh delivery approaches and open challenges close the account. Smart designs are the future, they argue.
Catalog record
| CREATOR | Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, Zhang G, Lu A, Yang Z. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review By Muhammad Kashif Riaz, Muhammad Adil Riaz, Xue Zhang, Congcong Lin, Ka Hong Wong, Xiaoyu Chen, Ge Zhang, Aiping Lu, Zhijun Yang Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms19010195 ABSTRACT Surface functionalization of liposomes can play a key role in overcoming the current limitations of nanocarriers to treat solid tumors, i.e., biological barriers and physiological factors. The phospholipid vesicles (liposomes) containing anticancer agents produce fewer side effects than non-liposomal anticancer formulations, and can effectively target the solid tumors. This article reviews information about the strategies for targeting of liposomes to solid tumors along with the possible targets in cancer cells, i.e., extracellular and intracellular targets and targets in tumor microenvironment or vasculature. Targeting ligands for functionalization of liposomes with relevant surface engineering techniques have been described. Stimuli strategies for enhanced delivery of anticancer agents at requisite location using stimuli-responsive functionalized liposomes have been discussed. Recent approaches for enhanced delivery of anticancer agents at tumor site with relevant surface functionalization techniques have been reviewed. Finally, current challenges of functionalized liposomes and future perspective of smart functionalized liposomes have been discussed. 1. INTRODUCTION The complex biology of solid tumors with various biological barriers, e.g., mononuclear-phagocyte system uptake and extravasation through vascular-endothelial layer, and physiological factors, e.g., hypoxia, low pH and raised interstitial-fluid pressure, highlights the need to design and formulate an efficient delivery system for anticancer agents [1]. The clinical application of many anticancer drugs have been hindered due to their limited water solubility, pharmacokinetics and potential adverse effects [2]. It has been estimated that in the USA during 2017 about 0.6 million deaths may occur due to all forms of cancers [3]. As regards the estimated cancer deaths, lung cancer tops the list, followed by colorectal cancer, pancreatic cancer, breast cancer and prostate cancer [4]. It was estimated that about 50% of all cancer deaths in the UK were due to common cancers: lung, breast, bowel and prostate [5]. Chemotherapeutic drugs damage both normal and tumor cells [6,7,8,9]. The most affected cells are bone marrow, gonads (sex organs), gastrointestinal tract and skin (hair follicle cells), liver and kidneys [10]. Several nanocarriers including liposomes have been utilized for cancer therapy. However, other nanocarriers have certain limitations. Nanoparticles have limited loading capacity, <5% payload as compared to nanoparticle weight [11,12]. Another major issue with nanoparticles is burst release of payload before reaching the intended site [11]. Antibody or sensitive molecules are inactivated upon interaction with hydrogels [13]. Gold nanoparticles have issues, e.g., biodistribution, pharmacokinetics and cationic ligand toxicity [14,15]. Limitations of the nanocarriers need to be addressed before establishment of their role in cancer therapy. To decrease side effects and achieve the efficient treatment of cancer, targeted delivery of small quantity of anticancer drugs using liposomes as drug delivery system have been suggested [16]. Liposomes facilitates in intracellular-delivery of anticancer drugs and prolongs the retention-time of encapsulated payload in cancer cells [17]. Liposomes can play a vital role in resolving the issues i.e., off-target effects of anticancer drugs by improving the pharmacokinetic-profile and pharmacological properties [18,19]. Several strategies have been employed for delivery of anticancer agents at tumor site, e.g., active and passive targeting. Active targeting with a combination of other approaches, e.g., stimuli sensitivity, is the current approach in tumor therapy. In this connection, liposomes are grafted with a variety of targeting ligands, e.g., peptides, aptamers, antibody fragments, etc., using different surface engineering techniques. Surface functionalization of liposomes with a variety of approaches has played an important role in formulation of a liposomal delivery system for efficient targeting, endocytosis and therapeutic-response. Surface functionalization and modification of liposomes using a variety of techniques have aided in addressing the current limitations of liposomes. In this regard, theranostic-liposomes with simultaneous functionalities of diagnosis and treatment in a single formulation is the latest approach in nanomedicine [20]. Liposomes can be engineered for a specific application using suitable surface functionalization and modification techniques, providing the key benefits in cancer therapy of prolonged circulation time, enhanced cellular-uptake, higher payload accumulation at tumor site, by passing lysosomal degradation and stimuli responsive payload release at intended site. This review article has been written with the following aims: To describe the current strategies for targeting of liposomes at malignant solid tumor sites, with a focus on latest trends in active targeting. Extracellular targeting, i.e., overexpressed receptors on cancer cells surface; intracellular targeting, i.e., over-expressed receptors in cytoplasm and nucleus; organelle targeting; and tumor-microenvironment or vasculature targeting have been reported. Targeting ligands for functionalization of liposomes with relevant surface engineering techniques have been described. Stimuli strategies for enhanced delivery of anticancer agents at requisite location using stimuli-responsive functionalized liposomes have been discussed. Recent approaches for overcoming the current limitations of liposomes and efficient delivery of anticancer agents at tumor site, e.g., functionalization of liposomes with two targeting ligands, modification of liposomes with simultaneous responsiveness to concurrent stimuli and dual functionalized liposomes, responsive to stimuli and grafted with targeting ligands have been reviewed. Further, the relevant functionalization techniques in designing and formulation of a smart liposome based nanocarrier have been explained. Finally, challenges and limitations of functionalized liposomes and future perspective of smart functionalized liposomes have been discussed. 2. LIPOSOMES AND THEIR CLASSIFICATION Liposomes have onion-like structures, and are among the most extensively studied nanocarriers for delivery of anticancer agents to tumor site, using a single or combination of targeting strategies [21]. Liposomes are vesicles having one or more concentric phospholipid bilayers separated by aqueous compartments [22]. Liposomes were first reported by Alec Bangham (1921–2010) in a research article published in 1964. At first, vesicles were called as “Banghasomes” or “multilamellar smectic mesophases”, and then the word “liposomes” was proposed by Gerald Weissmann, in which “lipos” means fat and “soma” means body [23,24,25,26]. Conventional liposomes are made up of phospholipid bilayers, and, when administered intravenously, are taken up by the reticuloendothelial system (RES), thus have short circulation times. Opsonin (a serum-protein) recognizes them as foreign substance, therefore, they are destroyed by phagocytes (a part of RES). To increase the circulation time, liposomes surface has been coated with a hydrophilic polymer, i.e., polyethylene glycol (PEG), increasing repulsive forces between liposomes and serum-components. Such surface modified liposomes have been termed as PEGylated or stealth liposomes (see Figure 1) [27]. Functionalization of liposomes with a suitable ligand, i.e., peptides, antibodies or their fragments, aptamers, small molecules, etc., for targeted delivery of anticancer agents at the requisite site, i.e., tumor, using overexpressed receptors as a docking-site have resulted in formation of ligand-targeted liposomes or targeted liposomes. Application of targeted liposomes, formulated by a variety of surface engineering techniques in cancer therapy, has demonstrated minimum off-target effects to healthy tissues. Immunoliposomes have been formulated by chemically coupling antibodies or their fragments to the liposomal surface, resulting in high specificity for their target antigens [28]. Multifunctional liposomes have the potential to overcome the current challenges of liposomal formulations with a single functionality. A combination of surface functionalization and modification techniques has been utilized to formulate a nanoscale liposomal formulation, with a variety of functionalities. Liposomes having two ligands, e.g., two peptides (dual functional liposomes) [29], liposomes carrying two ligands and two anticancer drugs [30],